
NKTX
Healthcare · Biotechnology · $85.2M market cap
$1.19-0.07 (-5.9%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -19.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | -0.40 | -0.45 | -12.5% |
| Aug 10, 2026 | After the close | -0.39 | -0.54 | -38.5% |
| May 13, 2026 | Time not confirmed | -0.36 | -0.37 | -2.7% |
| Mar 25, 2026 | After the close | -0.29 | -0.37 | -27.6% |
| Nov 10, 2025 | After the close | -0.30 | -0.29 | +3.3% |
| Aug 12, 2025 | After the close | -0.35 | -0.31 | +11.4% |
| May 14, 2025 | After the close | -0.45 | -0.43 | +4.4% |
| Mar 19, 2025 | Before the open | -0.40 | -0.35 | +12.5% |
| Nov 7, 2024 | After the close | -0.36 | -0.39 | -8.3% |
| Aug 13, 2024 | After the close | -0.51 | -0.34 | +33.3% |
| May 9, 2024 | After the close | -0.56 | -0.58 | -3.6% |
| Mar 21, 2024 | After the close | -0.59 | -0.57 | +3.4% |
| Nov 9, 2023 | After the close | -0.65 |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and…
| -0.52 |
| +20.0% |
| Aug 10, 2023 | Before the open | -0.68 | -0.68 | 0.0% |
| May 11, 2023 | After the close | -0.70 | -0.63 | +10.0% |
| Mar 16, 2023 | After the close | -0.64 | -0.67 | -4.7% |
| Nov 9, 2022 | After the close | -0.62 | -0.58 | +6.5% |
| Aug 11, 2022 | After the close | -0.59 | -0.61 | -3.4% |
| May 12, 2022 | After the close | -0.72 | -0.79 | -9.7% |
| Mar 17, 2022 | After the close | -0.90 | -0.69 | +23.3% |
| Nov 10, 2021 | After the close | -0.66 | -0.68 | -3.0% |
| Aug 12, 2021 | After the close | -0.59 | -0.66 | -11.9% |
| May 13, 2021 | After the close | -0.52 | -0.59 | -13.5% |
| Mar 25, 2021 | After the close | -0.44 | -0.55 | -25.0% |
| Nov 12, 2020 | After the close | -0.39 | -0.44 | -12.8% |
| Aug 20, 2020 | After the close | -6.71 | -6.08 | +9.4% |
| Apr 20, 2020 | Time not confirmed | — | -0.69 | — |